Company Research Report: Absci Corp

Company Overview

Name

Absci Corp

Mission

"Create better biologics for patients, faster."

Founded and By Whom

Founded by Sean McClain.

Headquarters

Vancouver, WA, USA

Additional Locations: New York City, NY, USA; Zug, Switzerland; Belgrade, Serbia.

Key People

Sean McClain: Founder, CEO & Director

Zach Jonasson, PhD: Chief Financial Officer & Chief Business Officer

Andreas Busch, PhD: Chief Innovation Officer

Karin Wierinck: Chief People Officer

Shelby Walker, JD: Chief Legal Officer

Amaro Taylor-Weiner, Ph.D.: Chief AI Officer

Wen Sha: Chief of Staff

Jens Plassmeier, PhD: SVP, Biologics Discovery Technology

Christine Lemke, PhD, DVM, MBA: SVP, Portfolio and Growth Strategy

Christian Stegmann, PhD, MBA: SVP, Drug Creation

Number of Employees

160+ Unlimiters

Revenue

No information is available.

Known For

Absci is known for using generative AI to design and validate de novo antibody candidates, potentially reducing the time to bring new drug leads into the clinic by over 50%.

Products

Products Offered

1. Integrated Drug Creation™ Platform
2. SoluPro® Technology
3. Generative AI Engine

High-Level Description

Integrated Drug Creation™ Platform

Our platform combines AI with synthetic biology to build and test millions of AI designs weekly. It moves from designs to data in as little as six weeks, facilitating the validation of new biologic-based therapeutics.

SoluPro® Technology

A multiplex synthetic biology approach generating billions of protein-protein interaction data to train machine learning models.

Key Features

1. Data to Train: Proprietary wet-lab assays generating extensive data.
2. AI to Create: Uses generative AI for novel antibody designs.
3. Wet Lab to Validate: An infrastructure for rapid functional validation of AI-generated designs.

Recent Developments

New Partnerships

Absci and PrecisionLife Partnership: Jointly develop AI-enabled drug pipeline (Dec 04, 2023).

Collaboration with AstraZeneca: Advance AI-driven oncology candidate (Nov 14, 2023).

Partnership with Almirall: Develop treatments for dermatological diseases (Nov 14, 2023).

Partnership with NVIDIA: To power and scale Absci's in silico technologies.

New Features

No information is available.

New Products Launched

No information is available.

Partnerships Highlight

EQRx: "Absci’s platform is enabling rapid drug discovery."

AstraZeneca: "De novo AI antibody creation platform for new oncology therapies."

NVIDIA: "Scaling AI technologies for positive impact."

Merck Global Health Innovation Fund: "Investing in transformative biopharmaceutical technologies."

Absci Technology

Drug Discovery Process

Data to Train

Utilizes SoluPro® technology to gather extensive high-quality data, optimizing the training of machine learning models for more accurate predictions.

AI to Create

Deploys generative AI to design novel antibodies, optimizing for various pharmacologic traits via a data-driven, iterative approach.

Wet Lab to Validate

Facilitates a quick turnaround from AI design to wet lab validation, in as little as six weeks, ensuring high-throughput, high-quality functional validation.

Conclusion

Absci Corp represents a pivotal shift in the biotechnology landscape by leveraging breakthrough advances in AI and synthetic biology to transform drug discovery into drug creation. Their commitment to shortening clinical timelines and increasing success rates has been validated through strategic partnerships and growing internal capabilities.

No additional commentary provided as per instructions.